Phase 1 Safety and Immunogenicity Evaluation of a Next-Generation DNA-Based Yellow Fever Vaccine
The first-in-human SAFYR trial demonstrated that Launch-iT YF, a next-generation DNA-based yellow fever vaccine, is safe and induces persistent humoral and cellular immune responses in healthy adults, supporting its further development as a scalable and adaptable vaccine platform.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Yellow fever is a dangerous viral disease carried by mosquitoes, capable of turning a mild fever into a severe, life-threatening illness that attacks the liver and causes bleeding. For decades, the only way to protect people has been a vaccine made from a weakened version of the virus itself. This traditional vaccine works incredibly well, often providing lifelong protection after a single shot, but it is difficult to make. The manufacturing process relies on growing the virus inside fertilized chicken eggs, a method that is slow, labor-intensive, and hard to scale up quickly when outbreaks occur. Because the virus must stay alive and active throughout the entire production and shipping process, the vaccine requires a strict cold chain, meaning it must be kept frozen or refrigerated at all times. These logistical hurdles have led to frequent shortages, leaving millions of people vulnerable. Scientists have long sought a new way to make this vaccine that is faster to produce, easier to ship, and just as effective, without relying on eggs or live virus during the manufacturing stage.
To address this challenge, a team of researchers tested a new type of vaccine called Launch-iT YF. Instead of injecting a pre-made virus, this vaccine delivers a small, circular piece of genetic material known as a DNA plasmid. Think of this plasmid as a set of instructions. Once injected into the skin, these instructions enter the person's own cells, which then read the code and begin building the weakened yellow fever virus themselves. This means the vaccine is essentially a factory that starts up inside the body, producing the live, weakened virus right where it is needed to trigger an immune response. Because the starting material is just DNA, it can be manufactured in standard bacterial tanks, is much more stable than a live virus, and does not require the same complex cold storage. The researchers wanted to see if this new approach was safe for humans and if it could successfully teach the immune system to fight off the disease.
In a carefully controlled trial involving healthy adults between the ages of 18 and 40, the team administered different doses of this DNA vaccine to see how the body reacted. The study was designed to be a first step, checking for safety and signs that the immune system was waking up to the threat. Participants received a single injection into the skin of their arm, with some receiving the vaccine at one spot and others at three spots to see if the method of delivery mattered. The researchers monitored the volunteers closely for any signs of illness or discomfort, from the day of the injection through a full year of follow-up visits. They also took blood samples to measure two key types of immune defenses: antibodies, which are proteins that can neutralize the virus, and T cells, which are immune cells that hunt down and destroy infected cells.
The results showed that the new vaccine was safe and well-tolerated. None of the volunteers experienced serious side effects that could be linked to the shot, and the most common reactions were mild, such as tiredness or a headache, which are typical for many vaccines. There was no clear pattern showing that higher doses caused more side effects. More importantly, the vaccine worked. In the group that received the middle dose injected at three spots, the highest number of people developed a strong immune response. Specifically, 8 out of 11 people in that group produced enough protective antibodies to be considered immune. These antibodies appeared within a month and remained at high levels for the entire year of the study. Alongside the antibodies, the vaccine also triggered a robust response from T cells, which are crucial for long-term protection. These immune cells showed a diverse and powerful ability to recognize the virus, with many of them producing multiple defense signals at once, a sign of a high-quality immune memory.
While the vaccine did not work for everyone, the fact that it successfully generated both antibodies and T cells in a significant portion of the participants is a major step forward. The researchers noted that the immune response took a little longer to appear than with the traditional egg-based vaccine, which makes sense because the body first had to use the DNA instructions to build the virus before it could start fighting it. This delay did not affect the strength of the final protection. The study also confirmed that the new technology is flexible; because the DNA instructions can be easily rewritten, this same platform could potentially be adapted to make vaccines for other diseases quickly, using the same manufacturing process. Although the trial was small and focused on healthy young adults, the findings provide strong evidence that this next-generation approach is feasible. The team is now working on a second version of the vaccine to improve the rate at which it works, aiming to create a tool that can be produced rapidly and shipped easily to protect people against yellow fever and other emerging threats.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.